Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.45 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 10/20 | 0.41 |
| ▸ | LPAR5 | Q9H1C0 | 10/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8093055 | 0.86 | HDAC1 (0.49) | HDAC3HDAC1HDAC2NCOR2ALDH1A1 | |
| SCHEMBL8647955 | 0.86 | HDAC3 (0.50) | HDAC3HDAC1HDAC2NCOR2LPAR1 | |
| SCHEMBL14004878 | 0.86 | HDAC3 (0.66) | HDAC3HDAC1HDAC2NCOR2ALDH1A1 | |
| SCHEMBL2655937 | 0.86 | ALDH1A1 (0.57) | HDAC3HDAC1HDAC2NCOR2ALDH1A1 | |
| SCHEMBL13078634 | 0.85 | HDAC3 (0.48) | HDAC3HDAC1HDAC2NCOR2ALDH1A1 | |
| SCHEMBL380193 | 0.84 | HDAC3 (0.58) | HDAC3HDAC1HDAC2NCOR2ALDH1A1 | |
| SCHEMBL409376 | 0.83 | HDAC1 (0.44) | HDAC3HDAC1HDAC2NCOR2CTSL | |
| SCHEMBL10170384 | 0.83 | HDAC1 (0.44) | HDAC3HDAC1HDAC2NCOR2CTSL | |
| SCHEMBL409375 | 0.83 | HDAC1 (0.44) | HDAC3HDAC1HDAC2NCOR2CTSL | |
| SCHEMBL4743834 | 0.83 | LTA4H (0.46) | ALDH1A1ALDH2MEP1BLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3103791-B1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-3103791-B1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-3103791-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-3103791-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2170076-B1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2170076-B1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9096559-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096559-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096559-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130137690-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
| US-20130137690-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
| US-20130137690-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
| US-8389553-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389553-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389553-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100324046-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324046-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324046-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-12-23 | — | — | US | disclosed |
| WO-2009002495-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137690-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | BRDT, HDAC4, HDAC5 | HDAC3 4/4885HDAC1 5/4885HDAC2 6/4885 |
| US-20100324046-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | BRDT, HDAC4, HDAC5 | HDAC3 4/4885HDAC1 5/4885HDAC2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.